Q2 2026 revenue of $5.36B up 4.9% YoY represents broad-based geographic growth, not a mature, dying category

• Q2 2026 revenue: $5.36 billion, up 4.9% YoY
• Emerging markets, Europe, and Hill's Pet Nutrition are all delivering simultaneously

↩ rebuts: “Bear's 'low-single-digit revenue growth is a death sentence' narrative”

eltaMD skincare acquisition ($750M from early 2025) is an underappreciated 2027–2028 earnings catalyst barely in consensus estimates yet

• eltaMD skincare acquisition from early 2025 ($750M)
• barely in the numbers yet
• Dermocosmetics is a structurally higher-growth adjacency, and we're only in year one of integration
• This is a 2027–2028 earnings driver that hasn't even shown up in consensus estimates

Q4'25 impairment of $866M was a one-time non-cash charge; underlying operating income was actually $1.019B; Q1 and Q2 2026 showing margin recovery

• $866M non-operating charge was a one-time, non-cash accounting adjustment
• underlying operating income that quarter was actually $1.019 billion
• Q1 and Q2 2026 are already showing margin recovery in that segment

↩ rebuts: “Bear's 'Q4'25 impairment spells doom' thesis”

The buyback flywheel creates a dual-engine EPS compounding machine through operating earnings growth AND denominator shrinkage

• Treasury stock: $28.9 billion (and climbing every quarter)
• TTM buybacks: ~$1.29 billion
• TTM dividends: ~$1.79 billion
• Total capital return: ~$3.08 billion against $4.46 billion FCF = 69% payout ratio
• Forward EPS of $4.10 vs. trailing $2.54
• Q4'25 loss of –$0.05 per share is the optical illusion

↩ rebuts: “Bear's focus on 'low' revenue growth rates”

CL's brand portfolio across 200+ countries and 60.4% gross margins/21% operating margins represent durable competitive moats that would cost tens of billions and decades to replicate

• Brand portfolio across 200+ countries
• Colgate, Palmolive, Hill's, Speed Stick, Irish Spring, Tom's of Maine, Ajax, eltaMD
• 60.4% gross margins and 21% operating margins
• Only Procter & Gamble and Estée Lauder operate at this level

63 consecutive years of dividend increases makes CL a defensive holding that pension funds and endowments chase on weakness

• 63 consecutive years of dividend increases
• Beta of 0.33
• Every pension fund, every endowment, every conservative allocator on earth has CL on their watchlist specifically because of this streak

Current MACD bearish crossover is a 4-session old pullback within an uptrend, not a reversal; price remains $5.45 above rising 200 SMA; RSI at 48.64 has room to fall, presenting bounce-buying opportunity

• CL closed at $91.46 on August 18
• MACD just crossed bearish
• Price is still $5.45 above the rising 200 SMA
• The 50 SMA at $91.32 is holding
• The MACD bearish crossover is four sessions old
• RSI at 48.64 isn't oversold—it has room to fall, but that also means the bounce-buying opportunity is approaching
• The technical report itself flags the 'trend pause' interpretation

↩ rebuts: “Bear's 'MACD just crossed bearish, short-term momentum is negative'”

Forward P/E of 22.3x is the relevant metric, barely above 5-year average of ~21x; Simply Wall St. analysis implies 30% DCF upside; trailing P/E of 36x is distorted by Q4'25 impairment

• P/E TTM is 36x (statistically distorted by the Q4'25 non-operating impairment)
• The forward P/E of 22.3x is the relevant read
• barely above CL's 5-year average of ~21x
• One Simply Wall St. piece flagged 30% DCF-implied upside

↩ rebuts: “Bear's 'stretched valuation' thesis”

CL's gross margins expanded to 61.5% in Q2'26 from 60.1% in Q2'25 despite rising input costs, demonstrating proven pricing power through inflationary cycles

• CL has demonstrated pricing power through every inflationary cycle since 2022
• gross margins actually expanded to 61.5% in Q2'26 from 60.1% in Q2'25, despite cost pressure
• Q2 already captured the bulk of the cost narrative, and management has shown they can lag-pass through pricing

↩ rebuts: “Bear's 'rising input costs from oil/Hormuz risk pressure margins'”

KMB's China diaper disruption is a peer-specific issue; CL doesn't make diapers; CL's Q2 2026 showed strength in emerging markets, not weakness

• KMB's China diaper disruption is a KMB-specific issue, not a CL issue
• CL's Q2 2026 results showed strength in emerging markets, not weakness
• CL makes toothpaste, pet food, and personal care—categories with much more defensive demand profiles

↩ rebuts: “Bear's 'Peer KMB cut 2026 guidance—sector headwind'”

U.S. weakness is largely a private-label penetration story, not a structural impairment; U.S. is only ~40% of revenue; innovation pipelines and premium positioning (Tom's of Maine, eltaMD) address this

• The U.S. is only ~40% of CL's revenue. The other 60% is firing
• The U.S. weakness is largely a private-label penetration story
• CL addresses this through innovation pipelines and premium brand positioning (Tom's of Maine, eltaMD)
• This isn't a structural impairment; it's a competitive dynamic that management has been navigating for years

↩ rebuts: “Bear's 'U.S. business showed weakness'”

Rising long-end yields, geopolitical risk, and 'higher for longer' rate environment favor high-quality, low-beta, dividend-paying compounders—CL's literal definition

• The 30-year Treasury just hit a 19-year high
• The U.S. national debt is approaching $40 trillion
• Polymarket shows 85% probability of zero Fed cuts in 2026
• The U.S.–Iran conflict is disrupting 600,000 bpd of oil supply
• This environment favors high-quality, low-beta, dividend-paying compounders with predictable cash flows and pricing power

↩ rebuts: “Bear's implied negative view of rising yields/risk environment”